Bifogade filer
PDF
Kurs
+3,98%
Kalender
| Est. tid* | ||
| 2025-02-25 | - | Bokslutskommuniké 2024 |
| 2024-11-29 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-28 | - | Årsstämma |
| 2024-05-31 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
| 2024-05-14 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-27 | - | Bokslutskommuniké 2023 |
| 2023-10-27 | - | Extra Bolagsstämma 2023 |
| 2023-10-27 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-30 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-31 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
| 2023-05-30 | - | Årsstämma |
| 2023-05-12 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-24 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-17 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
| 2022-05-16 | - | Årsstämma |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-22 | - | Bokslutskommuniké 2021 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-04 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
| 2021-06-03 | - | Årsstämma |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-12 | - | Bokslutskommuniké 2020 |
| 2020-11-13 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-05 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
| 2020-06-04 | - | Årsstämma |
| 2020-05-15 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-11-15 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-28 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-27 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
| 2019-05-24 | - | Årsstämma |
| 2019-05-17 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-11-21 | - | Kvartalsrapport 2018-Q3 |
| 2018-06-05 | - | Årsstämma |
| 2018-05-24 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-16 | - | Bokslutskommuniké 2017 |
| 2017-12-11 | - | Extra Bolagsstämma 2017 |
| 2017-10-25 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-30 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-24 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
| 2017-05-23 | - | Årsstämma |
| 2017-05-16 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-16 | - | Bokslutskommuniké 2016 |
| 2016-10-28 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-24 | - | Kvartalsrapport 2016-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Sektor | Hälsovård |
| Industri | Bioteknik |
Cyxone (publ), a biotech company in autoimmune diseases, announces today that CFO Henrik Hang leaves the company at his own request. Ola Skanung, previously the CFO at Cyxone, succeeds Henrik.
Henrik joined the company as CFO in August 2021 and has during his time in Cyxone contributed to, among other things, fundraising and restructuring to enable the planned development activities to be performed according to current regulations.
Ola Skanung will take over the role as CFO from Henrik as of November 2022.
"Henrik Hang has been a great asset to the company since he joined Cyxone. Henrik has performed several valuable changes in the company's internal workflow and structures. We are very grateful for his contributions and wish Henrik the best of luck in his future engagements. We are at the same time pleased to welcome Ola Skanung to Cyxone. Ola knows the company well from previous years and brings a lot of knowledge and experience in his role," comments Carl-Magnus Högerkorp, acting CEO, Cyxone.
Contact
Carl-Magnus Högerkorp, acting CEO
Tel: +46 (0)70 781 88 12
Email: carl.hogerkorp@cyxone.com
The information was submitted for publication, through the agency of the contact person set out above, at 15.00 CEST on 31 August 2022.
About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com